| 2.04 0.03 (1.49%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.21 | 1-year : | 2.56 |
| Resists | First : | 1.89 | Second : | 2.2 |
| Pivot price | 1.7  |
|||
| Supports | First : | 1.4 | Second : | 1.17 |
| MAs | MA(5) : | 1.5 |
MA(20) : | 1.75 |
| MA(100) : | 3.22 |
MA(250) : | 4.89 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 7.5 |
| RSI | RSI(14): 29.8  |
|||
| 52-week | High : | 21.95 | Low : | 1.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ONVO ] has closed above bottom band by 10.1%. Bollinger Bands are 79.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.41 - 1.42 | 1.42 - 1.43 |
| Close: | 1.45 - 1.47 | 1.47 - 1.49 |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Wed, 23 Apr 2025
Organovo Holdings, Inc. Announces Name Change to VivoSim Labs, Inc. and New Ticker Symbol "VIVS" - Quiver Quantitative
Wed, 23 Apr 2025
Organovo Holdings Inc Name Change To VivoSim Labs Effective April 24, 2025 - TradingView
Wed, 23 Apr 2025
Organovo rebrands as VivoSim Labs, debuts new ticker - Investing.com
Wed, 19 Mar 2025
Organovo Announces 1-for-12 Reverse Stock Split To Maintain Nasdaq Compliance - Nasdaq
Wed, 19 Mar 2025
Organovo announces 1-for-12 reverse stock split - Investing.com
Wed, 19 Mar 2025
Organovo's Major Stock Restructuring: 1:12 Reverse Split Coming March 20 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.29e+006 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 115 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.228e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 450 % |
| Return on Equity (ttm) | -123.4 % |
| Qtrly Rev. Growth | 122000 % |
| Gross Profit (p.s.) | 336.28 |
| Sales Per Share | -334.87 |
| EBITDA (p.s.) | -4.52212e+006 |
| Qtrly Earnings Growth | -10.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 6.64 |
| Dividend | 0 |
| Forward Dividend | 73380 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|